Phase 1 Hepatitis C Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People whose main reason for the clinic visit is advanced (stage D) heart failure, and who have been on a steady, unchanged dose of a heart-support drip medication (dobutamine or milrinone) for at least the past 28 days
- People who have had imaging (such as an echocardiogram) within the past 12 months showing that their heart's pumping strength is below 50%
- People whose inotrope (heart-support drip) dose has been stable and who have not been hospitalised in the past month
- People aged 21 or older who are willing and able to sign a written consent form
- People who are willing and able to follow the study plan, including self-administering the study treatment and taking part in an exercise protocol
- People whose blood test at screening shows a C-reactive protein (an inflammation marker) level above 2 mg/L
Who may not be able to join:
- People who have other significant medical conditions — such as a recent heart attack, poorly controlled blood pressure, certain heart rhythm problems, serious lung disease, or nerve/muscle disorders affecting breathing — that could interfere with the study
- People who have had, or are planning to have, a cardiac resynchronisation therapy (CRT) device procedure or heart valve surgery within the past 3 months or upcoming
- People who have had, or are planning to have, a mechanical heart pump (left ventricular assist device) fitted or a heart transplant within the next 3 months
- People who have used immune-suppressing or strong anti-inflammatory medicines (including certain steroid tablets) in the past 14 days (confirm with trial site for exact medicines included)
- People who have a long-term inflammatory condition such as rheumatoid arthritis or lupus
- People who have an active infection of any kind, or a chronic or recurring infectious disease such as hepatitis B, hepatitis C (unless hepatitis C is fully suppressed with no detectable virus), or HIV/AIDS
- People who have had, or currently have, a cancer that is being treated with targeted therapy within the past 5 years — though people with certain very early-stage or localised skin cancers may still be considered (confirm with trial site)
- People with very advanced (stage 5) kidney disease or who are on dialysis or another kidney-replacement treatment
- People with a low white blood cell count (neutropenia), below specific thresholds depending on ethnic background
- People who are pregnant or breastfeeding
- People who experience chest pain, high blood pressure, heart rhythm problems, abnormal ECG readings, or other limitations during the baseline walking test that affect the result
- People who have a known allergy or sensitivity to the study drug anakinra, or to products derived from E. coli bacteria
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Azita Talasaz, Virginia Coomonwealth University
Phone: 8048284583
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percent reduction in high-sensitive C-Reactive Protein (hsCRP, a biomarker for IL-1 activity)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.